Dexamethasone‐Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High‐Dose Cisplatin: A Randomized Noninferiority Study

BACKGROUND: To reduce the overall exposure to dexamethasone (DEX) in patients receiving cisplatin‐based chemotherapy, we evaluated the noninferiority of DEX on day 1, with or without low‐dose DEX on days 2 and 3, combined with an oral fixed‐dose combination of netupitant and palonosetron (NEPA), com...

Descripción completa

Detalles Bibliográficos
Autores principales: Celio, Luigi, Cortinovis, Diego, Cogoni, Alessio Aligi, Cavanna, Luigi, Martelli, Olga, Carnio, Simona, Collovà, Elena, Bertolini, Federica, Petrelli, Fausto, Cassano, Alessandra, Chiari, Rita, Zanelli, Francesca, Pisconti, Salvatore, Vittimberga, Isabella, Letizia, Antonietta, Misino, Andrea, Gernone, Angela, Bonizzoni, Erminio, Pilotto, Sara, De Placido, Sabino, Bria, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Symptom Management and Supportive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488764/
https://www.ncbi.nlm.nih.gov/pubmed/34101934
http://dx.doi.org/10.1002/onco.13851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488764/
https://www.ncbi.nlm.nih.gov/pubmed/34101934
http://dx.doi.org/10.1002/onco.13851

Ejemplares similares